Synspira

Synspira, founded in early 2017, develops inhaled therapies for pulmonary diseases such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and pneumonia through an exclusive field license to Synedgen's Glycomics technology platform and its associated pulmonary delivery assets. The unique characteristics of Synspira’s proprietary modified polysaccharide agents have the potential to address significant unmet needs associated with these pulmonary conditions, chronic infections, and related inflammation, which often lead to exacerbations, hospitalizations, and ultimately irreversible declines in lung function.